Trials / Unknown
UnknownNCT04377243
Immunotherapy of Chronic Kidney Failure
Phase II Trial of V8 in Treating Kidney Failure
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Immunitor LLC · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Kidney failure can result from inflammatory renal disease in the context of autoimmunity because the kidney is targeted by host's immune response against self. There are many causes to this, but abnormal kidney function tests, i.e., BUN and creatinine, can reveal the disease. Oral delivery of kidney cells is ought to produce the immune tolerance - phenomenon is known as oral tolerance. Preliminary studies produced convincing evidence that this hypothesis holds true and has not produced any adverse side effects. Intended open label Phase II aims to confirm these findings.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | V8 | one pill per day either V8 or placebo |
Timeline
- Start date
- 2020-06-16
- Primary completion
- 2021-05-15
- Completion
- 2021-09-01
- First posted
- 2020-05-06
- Last updated
- 2020-05-08
Locations
1 site across 1 country: Mongolia
Source: ClinicalTrials.gov record NCT04377243. Inclusion in this directory is not an endorsement.